黑料网

Equilibrium in the symbiotic gut-host relationship and disequilibrium in gut microbial communities and microbiota functions are now clearly tied to the health of the host [11]. May be a key component of the pathophysiology of illnesses affecting the intestines and other organs, such as diabetes and kidney disease [12]. Adiposity and poor glucose metabolism are indeed linked to low bacterial richness and compositional changes in the intestinal microbiota of people with T2D and obesity, according to observational studies in humans [13]. By demonstrating that the "lean/obese" phenotypes can be transmitted in part via faecal microbiota transplantation, experimental models and clinical trials have further demonstrated the mechanistic relevance of the microbiome in host metabolism and the pathogenesis of metabolic diseases [14]. The gut-kidney axis, a term used to describe the tangled bidirectional interaction between the intestinal microbiome and kidneys, is especially important when chronic renal disease is apparent [15]. In actuality, CKD causes uremic toxins of microbiological origin to accumulate in the bloodstream. The taxonomic and functional characteristics of the gut microbiota in CKD and DKD will be briefly discussed in this review, along with the most recent research on the role of microbial metabolic products in controlling inflammatory and damaging processes in the diabetic kidney. Last but not least, we'll talk about potential future paths in the gut-kidney sector and what makes prospective microbiome-targeting treatments for Important pathophysiological factors contributing to the renal injury and dysfunction associated with DKD include hyperglycemia, vascular damage, and inflammation. Importantly, DKD's pathological changes include the gut-kidney axis is present at equilibrium but only becomes apparent in CKD. Uremic toxins build up in the blood when renal function declines and the colon becomes the primary excretory pathway (2). Urea levels thereafter raising importantly, the free forms of uremic metabolites appear to account for their toxicity. Despite the fact that Sahfi was unable to substantiate it, the link between total free and protein-bound plasma PCS and IS and risk of cardiac mortality in 1273 HD patients from the multicenter HEMO trial became substantial when looking at a subgroup of patients with low levels of albumin. As a result, albumin-free uremic metabolites may serve as more accurate predictors of poor clinical outcomes. In a very recent study by Wang, multidimensional data integration of the microbiome profiles, serum and faecal metabolomes, and the metabolite landscapes of 69 healthy controls and 223 ESKD patients revealed a close relationship between the metabolite landscapes of the faeces and the serum, which was in turn related to and determined by the gut microbiota profiles. In fact, in individuals with ESKD, the faecal she had a previable preterm rupture of membranes when she went to the hospital with vaginal fluid leaks.

Discussion

Anhydramnios and a singleton foetus with a weight estimate of 492 g were discovered during an ultrasound scan. Neoatology and maternal-fetal medicine were consulted. The patient received extensive counselling regarding her prognosis, but she still wanted to carry the pregnancy to term. Neither labour nor an intraamniotic infection were clinically evident. She finished a course of latency antibiotics and a course of betamethasone. The patient was stable and showed no signs of intraamniotic infection or premature labour up until 24 weeks and 2 days into the pregnancy, at which point a fever was noticed. She started having excruciating contractions. A magnesium sulphate regimen was initiated for the patient. The kidneys have the capacity to compensate even as renal failure progresses, and there may be extensive kidney fibrosis without detectable changes in GFR. Patients with DN and intact GFR who only have proteinuria may be hiding a risk of developing severe renal disease and maybe even ESRD. The only recognised methods to limit the course of renal disease postpartum are vigorous hyperglycemia and blood pressure control in the absence of non-invasive technologies to assess underlying disease load. Numerous attempts have been made to use non-invasive imaging to assess renal fibrosis because it is a crucial part of the final common pathway leading to ESRD. An experiment recently showed that magnetic resonance elastography and magnetic resonance arterial Non-invasive assessment of the level of renal fibrosis burden in patients at risk of disease development prior to evident reductions in GFR may provide more precise renal assessments without the requirement for renal biopsy. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have demonstrably been proved to be helpful in lowering activation of the renin-angiotensin-aldosterone pathway, in addition to better glycemic and blood pressure control, in slowing the course of diabetic nephropathy. Although some medications should not be used during pregnancy due to the impact they have on the foetus, they should be started after delivery. However, extremely minute amounts of many of these substances have been found in breast milk. Since enalapril has the most published data to support its use, it is frequently chosen above other alternatives one study determined the degree given the clinically proven efficacy of RAAS blocking, and a risk/benefit analysis of its use while nursing should be conducted. Factors like isk can cause DN to proceed quickly to ESRD.

Conclusion

To comprehend the nature of the illness behaviour in this subpopulation, additional researches with a bigger sample size are required. New non-invasive screening methods that evaluate the burden of underlying fibro-sclerotic illness can also offer important information about the likelihood of disease development. Despite the uptitration of her first insulin regimen (Humalog: 6 units with breakfast, 7 units with lunch, and 20 units with supper; Levemir: 15 units in the morning and 12 units in the afternoon), her diabetes remained uncontrolled for the balance of her pregnancy. She kept having glycosuria. Her systolic and diastolic blood pressure varied from 140 to 158 and 80 to 98 mmHg, respectively. Labetalol 300 mg twice daily, nifedipine extended-release 60 mg daily, and furosemide 80 mg twice daily were added to her hypertension regimen. Despite these modifications, her hypertension remained poorly controlled, with blood pressure readings until delivery ranging from 68 to 120 mmHg diastolic and 130 to 184 mmHg systolic. Around 12 weeks into her pregnancy, she also began taking 81 mg of aspirin daily to lower her risk of preeclampsia. Her blood pressure was treated with intravenous labetalol when she arrived at the hospital at 36 weeks and 0 days pregnant with contractions and was found to have very high blood pressure, measuring 170-180 mmHg systolic and 90-100 mmHg diastolic. Misoprostol for cervical ripening and magnesium sulphate administration started the labour induction process. Fetal heart rate slowed down soon after misoprostol was given, which necessitated an emergent caesarean delivery and bilateral tubal ligation. She gave birth to a healthy female newborn weighing 2095 g, within normal range for gestational age, with Apgar scores of 8 and 9. She continued to take magnesium sulphate for 24 hours after giving birth, and blood pressure was eventually controlled with amlodipine 10 mg daily. Department for Chronic Disease Convergence Research, Korea National Institute of Health, Cheongju, Republic of Korea; Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Republic of Korea; Division of Life Sciences, College of Life Sciences, Korea University, Seoul, Republic of Korea.

Acknowledgement

None

Conflict of Interest

None

References

1. Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z (2019) Medicina 55.

, ,

2. Gheith O, Farouk N, Nampoory N, Halim MA, Al Otaibi T (2016) J Nephropharmacol 5: 49-56.

, ,

3. Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, et al. (2020) Diabetes Res Clin Pract 162: 108072.

, ,

4. Wang M, Yang Y, Liao Z (2020) World J Diabetes 11: 227-238.

, ,

5. Wang M, Tan Y, Shi Y, Wang X, Liao Z, et al. (2020) Front Endocrinol 11: 568.

, ,

6. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, (2019) Diabetes Res Clin Pract  157: 107843.

, ,

7.  (1992) Diabetes Care 15: 495-501.

, ,

8. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, et al. (2004) BMJ 328: 1105.

, ,

9. Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, et al. (2005) HTA.

, ,

10. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, et al. (2011) Kidney Int 79: 1331-1340.

, ,

11. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, et al. (2003) Kidney Int 63: 225-232.

, ,

12. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, et al. (2015) World J Gastroenterol 21: 8787-8803.

, ,

13. Ramezani A, Massy ZA, Meijers B, Evenepoel P, Vanholder R, et al. (2016) Am J Kidney Dis 67: 483-498.

, ,

14. Nymark M, Pussinen PJ, Tuomainen AM, Forsblom C, Groop PH, et al. (2009) FinnDiane Study Group. Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes. Diabetes Care 32: 1689-1693.

, ,

15. Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, et al. (2013) Kidney Int 83: 308-315.

, ,